Posted by Michael Wonder on 08 Feb 2016
U.S. FDA approves expanded use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for additional challenging-to-treat patients with genotype 1 or genotype 3 chronic hepatitis C
5 February 2016 - Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrence.
For more details, go to: http://news.bms.com/press-release/hepc/us-fda-approves-expanded-use-bristol-myers-squibbs-daklinza-daclatasvir-additiona
